Thomas M. Aaberg Jr., MD

Aaberg is chief medical officer at Neurotech Pharmaceuticals. He is a retina specialist with Retina Specialists of Michigan, and an assistant clinical professor at Michigan State University in East Lansing.

Articles by Thomas M. Aaberg Jr., MD

(Image credit: Christina Y. Weng, MD, MBA, FASRS, and Thomas M. Aaberg Jr., MD) The Retina TL;DR with Dr. Weng: Marking a milestone in MacTel with Thomas M. Aaberg Jr., MD

The Retina TL;DR with Dr. Weng: Marking a MacTel milestone with Thomas M. Aaberg Jr., MD

ByChristina Y. Weng, MD, MBA, FASRS,Thomas M. Aaberg Jr., MD

September 11th 2026

In the latest episode of The Retina TL;DR with Dr. Weng, host Christina Y. Weng, MD, MBA, FASRS, talks with Dr. Aaberg about the science, clinical data, and real-world reception of the first FDA-approved treatment for MacTel type 2.

Thomas M. Aaberg Jr., MD

Articles by Thomas M. Aaberg Jr., MD

The Retina TL;DR with Dr. Weng: Marking a MacTel milestone with Thomas M. Aaberg Jr., MD

Latest Updated Articles

Trending on Eye Care Network - Ophthalmology Times

Retina Society 2026: MCO-010 optogenetic therapy maintains visual acuity gains through 4 years in advanced RP

Retina Society 2026: Medium-dose OCU410 gene therapy cuts geographic atrophy progression by up to 32% in phase 2 trial

Retina Society 2026: LUGANO secondary data show reduced treatment burden with vorolanib insert despite missed primary end point

Beyond the phenotype: Aqueous humor sampling moves retinoblastoma toward personalized therapy

Aurion Biotech completes enrollment in phase 3 ASTRA study of AURN001 for corneal edema secondary to corneal endothelial dysfunction